LMP Capital and Income Fund Inc. SCD
15.28 USD +0.28 (+1.87%)
At closeNov 11, 2026, 4:00 PM EST
15.28 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
15.19 Day range 15.40
13.79 52-week range 16.18
- YTD
- +3.17%
- 1 year
- +2.76%
News
globenewswire.com SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90,…
globenewswire.com FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER,…
gurufocus.com Roche launches newborn screening test for three severe genetic conditions Roche launches newborn screening test for three severe genetic conditionsPR NewswireBERLIN, Sept. 30, 2026This test expands Roche's early diagnostics portfolio
seekingalpha.com SCD: High Midstream/Low Bond Exposure Is A Good Combination LMP Capital & Income Fund offers a 9.23% yield, emphasizing income and inflation protection via high allocations to MLPs and midstream energy equities. SCD's portfolio is differentiated by a 24.5%…
seekingalpha.com 10 Best CEFs This Month: Average Yield Of Near 10% (August 2026) The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% yield and nearly 5% NAV discount. Selections emphasize sector…
prnewswire.com Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term…
seekingalpha.com 10 Best CEFs This Month: Average Yield Of Near 10% (July 2026) The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and nearly 7.7% NAV discount. Selections emphasize sector…
defenseworld.net LMP Capital and Income Fund (NYSE:SCD) Stock Price Passes Below 200 Day Moving Average – Time to Sell? LMP Capital and Income Fund Inc. (NYSE: SCD - Get Free Report) shares crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of…
prnewswire.com Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's…
seekingalpha.com 10 Best CEFs This Month: Average Yield Of Near 10% (June 2026) The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.8% plus yield and nearly 7.5% NAV discount. Selections emphasize…
seekingalpha.com SCD: Gets The Job Done But Not The Most Efficient Income Fund LMP Capital and Income Fund maintains a 9.2% yield, with management expressing confidence in sustaining current distributions through August. Recent performance and distribution consistency have been…
gurufocus.com Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5--11, at the European Hematology Association Congress and Announces Additional Global Regulatory Su [url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVYÂ (exagamglogene autotemcel
seekingalpha.com 10 Best CEFs This Month: Average Yield Of 9% Plus (May 2026) The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9% plus yield and nearly 7.5% NAV discount. Selections emphasize sector…
gurufocus.com Emmaus Life Sciences Reports Quarterly Financial Results Emmaus Life Sciences, Inc. (OTCQB: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its
businesswire.com LMP Capital and Income Fund Inc (NYSE: SCD) (the “Fund”) Announces Portfolio Management Team Update NEW YORK--(BUSINESS WIRE)--Category: Fund Announcement.
prnewswire.com Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for…
defenseworld.net Allspring Global Investments Holdings LLC Makes New Investment in LMP Capital and Income Fund Inc. $SCD Allspring Global Investments Holdings LLC purchased a new position in LMP Capital and Income Fund Inc. (NYSE: SCD) during the undefined quarter, according to its most recent disclosure with the…
prnewswire.com Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol 98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcode…
seekingalpha.com SCD: Unique CEF Could Be Well-Positioned To Outperform In The Current Environment LMP Capital & Income Fund (SCD) offers a 9.63% yield, higher than broad equity indices and most peers, with a sustainable distribution profile. SCD's overweight energy allocation (14.05%) positions…
globenewswire.com Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
benzinga.com LMP Capital And Income Fund Raises $87M In Oversubscribed Rights Offering LMP Capital and Income Fund Inc. (NYSE:SCD) ("SCD" or the "Fund") announced today the completion of its transferable rights offering (the "Offer"). The Offer expired at 5:00 PM Eastern Time on July…
benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 361 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 1076 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning session, 255 companies made new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Friday During Friday's morning session, 235 stocks hit new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET on Thursday, 258 companies set new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Wednesday During Wednesday's morning trading, 251 companies set new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Tuesday Tuesday morning saw 244 companies set new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Monday Before 10 a.m. ET Monday, 296 stocks made new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Tuesday's morning session saw 391 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday Before 10 a.m. ET Friday, 188 stocks made new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET Thursday, 194 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Tuesday's morning session saw 173 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's morning session saw 160 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday This morning 792 companies reached new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday On Friday morning, 417 companies achieved new highs for the year.
benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET on Thursday, 441 companies set new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Tuesday This morning 263 companies set new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Monday On Monday morning, 415 companies achieved new highs for the year.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday On Thursday morning, 420 companies hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday
- benzinga.com Stocks That Hit 52-Week Lows On Monday
- benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com Stocks That Hit 52-Week Highs On Thursday
- benzinga.com St. Jude Medical Announces CE Mark Approval of Smaller ICD with Physician-Inspired Shape
- benzinga.com LMP Capital and Income Fund Announces Preliminary Results of Tender Offer
- benzinga.com LMP Capital and Income Fund Inc. Announces Final Results of Tender Offer
- benzinga.com LMP Capital and Income Fund Inc. Announces Preliminary Results of Tender Offer
- benzinga.com LMP Capital and Income Fund Announces About 16.8M Shares Tendered At $14.15/Share